Durvalumab: tested in a combination

295 studies: another drug in the study is under test too. Page 3 of 3. Open to participants first (78), then studies with results posted, then the rest; newest registration first within each.

• Durvalumab and Lenvatinib in Participants With Advanced and Recurrent Endometrial CarcinomaStatus unknownNCT04444193Not applicableReport a problem
• Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological MalignanciesActive, not recruitingNCT04395079Phase 2Report a problem
• Maintenance With Olaparib or Selumetinib + Durvaluma for m-PDAC Guided by BRCAness and KRAS Status.Active, not recruitingNCT04348045Phase 2Report a problem
• Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm StudyStatus unknownNCT04314297Phase 2Report a problem
• Anlotinib In Combination With PD-1/L1 Inhibitor As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm StudyStatus unknownNCT04313660Phase 2Report a problem
• Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)Active, not recruitingNCT04238637Phase 2Report a problem
• Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid CarcinomaCompletedNCT04224337Phase 2Report a problem
• Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction AdenocarcinomaCompletedNCT04221555Phase 2Report a problem
• A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE TrialActive, not recruitingNCT04216290Phase 2Report a problem
• Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal MelanomaWithdrawnNCT04184518Phase 2Report a problem
• RICE: Radio-Immuno-Chemotherapy of Cancer of the EsophagusActive, not recruitingNCT04159974Phase 2Report a problem
• Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRCWithdrawnNCT04145193Phase 2Report a problem
• Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast CancerWithdrawnNCT04088032Early Phase 1Report a problem
• Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.Active, not recruitingNCT04053322Phase 2Report a problem
• Tri Association in Patient With Advanced Epithelial Ovarian Cancer in RelapseStatus unknownNCT04015739Phase 2Report a problem
• Therapy for High-Risk HPV 16-Positive Oropharynx Cancer PatientsWithdrawnNCT04001413Phase 2Report a problem
• Study of Olaparib and Durvalumab in IDH-Mutated Solid TumorsActive, not recruitingNCT03991832Phase 2Report a problem
• A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5)Status unknownNCT03975114Phase 2Report a problem
• Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLCActive, not recruitingNCT03965468Phase 2Report a problem
• A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLCTerminatedNCT03963414Phase 1Report a problem
• Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction AdenocarcinomaActive, not recruitingNCT03959293Phase 2Report a problem
• Durvalumab and Olaparib in Metastatic or Recurrent Endometrial CancerStatus unknownNCT03951415Phase 2Report a problem
• Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)Active, not recruitingNCT03944772Phase 2Report a problem
• Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:Active, not recruitingNCT03875573Phase 2Report a problem
• Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid TumorsActive, not recruitingNCT03851614Phase 2Report a problem
• Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative TreatmentCompletedNCT03847428Phase 3Report a problem
• Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR MutationActive, not recruitingNCT03833154Phase 3Report a problem
• hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study"Status unknownNCT03824691Phase 2Report a problem
• A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLCActive, not recruitingNCT03819465Phase 1Report a problem
• Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver MetastasesWithdrawnNCT03802747Phase 1Report a problem
• A Study of Durvalumab in Combination With Doxorubicin for Advanced Soft Tissue SarcomaCompletedNCT03802071Phase 1/2Report a problem
• A Study of Pazopanib and Durvalumab for Metastatic Soft Tissue SarcomaCompletedNCT03798106Phase 2Report a problem
• Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral CavityActive, not recruitingNCT03784066Phase 1/2Report a problem
• A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular CarcinomaActive, not recruitingNCT03778957Phase 3Report a problem
• Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.Status unknownNCT03737968Phase 2Report a problem
• ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung CancerCompletedNCT03732664Phase 1Report a problem
• FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/PaclitaxelCompletedNCT03723967Phase 2Report a problem
• An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)Status unknownNCT03699449Phase 2Report a problem
• Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial CancerActive, not recruitingNCT03682068Phase 3Report a problem
• Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCCCompletedNCT03624231Phase 2Report a problem
• Cisplatin or ImmunoTHerapy in Association With Definitive Radiotherapy in HPV-related oropharyngEal Squamous Cell Carcinoma: a Randomized Phase II Trial.CompletedNCT03623646Phase 2Report a problem
• Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell CanerTerminatedNCT03618134Phase 1/2Report a problem
• Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder CancerActive, not recruitingNCT03601455Phase 2Report a problem
• Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast CancerActive, not recruitingNCT03594396Phase 1/2Report a problem
• Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric CancerActive, not recruitingNCT03579784Phase 2Report a problem
• Neoadjuvant CCRT With Gemcitabine/Durvalumab (MEDI4736) Followed by Adjuvant Gemcitabine/Durvalumab(MEDI4736) in Resectable or Borderline Resectable Pancreatic CancerActive, not recruitingNCT03572400Phase 2Report a problem
• NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial CarcinomaActive, not recruitingNCT03549715Phase 1/2Report a problem
• Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast CancerCompletedNCT03544125Phase 1Report a problem
• Durvalumab Plus Olaparib Administered Prior to Surgery of Resectable Urothelial Bladder Cancer (NEODURVARIB)CompletedNCT03534492Phase 2Report a problem
• Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid TumorsCompletedNCT03509012Phase 1Report a problem
• Assessing the Combination of Durvalumab (MEDI4736) and Trabectedin in Solid TumorsWithdrawnNCT03496519Phase 1Report a problem
• Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCCActive, not recruitingNCT03410615Phase 2Report a problem
• Neoadjuvant and Adjuvant Durvalumab in Combination With Neoadjuvant Chemotherapy in Patients With Operable Urothelial Cancer.CompletedNCT03406650Phase 2Report a problem
• Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)CompletedNCT03345810Phase 2Report a problem
• Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the BladderActive, not recruitingNCT03317158Phase 1/2Report a problem
• Immunotherapy With Neo-adjuvant Chemotherapy for OVarian CancerCompletedNCT03249142Phase 1/2Report a problem
• Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCLWithdrawnNCT03212807Phase 2Report a problem
• Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for LymphomaStatus unknownNCT03161223Phase 1/2Report a problem
• Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell CancerCompletedNCT03144778Phase 1Report a problem
• Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLCWithdrawnNCT03130764Phase 2Report a problem
• Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid CancerCompletedNCT03122496Phase 1Report a problem
• Durvalumab Alone or With Tremelimumab in Refractory Germ Cell TumorsTerminatedNCT03081923Phase 2Report a problem
• Durvalumab, Cetuximab and Radiotherapy in Head Neck CancerStatus unknownNCT03051906Phase 1/2Report a problem
• Durvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naïve Biliary Tract CancerActive, not recruitingNCT03046862Phase 2Report a problem
• Durvalumab and Endocrine Therapy in ER+/Her2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractant ExposureCompletedNCT02997995Phase 2Report a problem
• Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal CancerActive, not recruitingNCT02983578Phase 2Report a problem
• A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced MalignanciesCompletedNCT02978482Phase 1Report a problem
• Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal CancerActive, not recruitingNCT02962063Phase 1/2Report a problem
• Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid TumorsTerminatedNCT02938793Phase 2Report a problem
• Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck.CompletedNCT02882308Phase 2Report a problem
• Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic CancerWithdrawnNCT02868632Phase 1Report a problem
• MEDI4736 Combinations in Metastatic Renal Cell CarcinomaCompletedNCT02819596Phase 2Report a problem
• Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before SurgeryActive, not recruitingNCT02812420Early Phase 1Report a problem
• Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal CancersCompletedNCT02777710Phase 1Report a problem
• Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell CarcinomaCompletedNCT02762006Phase 1Report a problem
• Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy TrialActive, not recruitingNCT02678182Phase 2Report a problem
• National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung CancerCompletedNCT02664935Phase 2Report a problem
• Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid TumorsCompletedNCT02658214Phase 1Report a problem
• Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic CancersCompletedNCT02639026Phase 1Report a problem
• A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1)Status unknownNCT02588131Phase 2Report a problem
• MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)CompletedNCT02549651Phase 1Report a problem
• Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy RegimensActive, not recruitingNCT02537418Phase 1Report a problem
• Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous MelanomaWithdrawnNCT02535078Phase 1/2Report a problem
• Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...Active, not recruitingNCT02484404Phase 1/2Report a problem
• SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast CancerActive, not recruitingNCT02299999Phase 2Report a problem
• Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer AgentsActive, not recruitingNCT02264678Phase 1Report a problem
• A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck CancerCompletedNCT02262741Phase 1Report a problem
• A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid TumorsCompletedNCT02261220Phase 1Report a problem
• AZD9291 in Combination With Ascending Doses of Novel TherapeuticsActive, not recruitingNCT02143466Phase 1Report a problem
• Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ MesotheliomaCompletedNCT02141347Phase 1Report a problem
• Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic SyndromeCompletedNCT02117219Phase 1Report a problem
• SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC PatientsCompletedNCT02117167Phase 2Report a problem
• Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib AloneCompletedNCT02027961Phase 1Report a problem
• A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung CancerCompletedNCT02000947Phase 1Report a problem
• A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid TumoursCompletedNCT01938612Phase 1Report a problem

← Durvalumab